Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoantigen Vaccine deepGeneAI-001 + Sintilimab in GI Tumors
NCT07067385Phase 1Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jul 2025
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial (2 cohorts), sponsored by Ruijin Hospital. Primary endpoints: Adverse events as graded by CTCAE v5.0 up to 2.5 years, Serious adverse events as graded by CTCAE v5.0 up to 2.5 years and 1 more. Started Jul 2025; status: recruiting.
Beyond the preview
Go deeper on NCT07067385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07067385.